blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2305282

EP2305282 - Prevention and treatment of amyloidogenic disease [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  18.11.2016
Database last updated on 02.04.2025
Most recent event   Tooltip13.01.2017Lapse of the patent in a contracting state
New state(s): CH, LI
published on 15.02.2017  [2017/07]
Applicant(s)For all designated states
Janssen Alzheimer Immunotherapy
Airton Road
Tallaght
Dublin 24 / IE
[2013/28]
Former [2011/14]For all designated states
Janssen Alzheimer Immunotherapy
Little Island Industrial Estate
Little Island, County Cork / IE
Inventor(s)01 / Schenk, Dale B.
1542 Los Altos Drive
Burlingame, CA 94010 / US
 [2013/28]
Former [2011/14]01 / Schenk, Dale B.
1542 Los Altos Drive
Burlingame, CA 94010 / US
Representative(s)Bullett, Rachel Margaret, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2011/14]Bullett, Rachel Margaret, et al
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Application number, filing date10182575.030.11.1998
[2011/14]
Priority number, dateUS19970067740P02.12.1997         Original published format: US 67740 P
US19980080970P07.04.1998         Original published format: US 80970 P
[2011/14]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2305282
Date:06.04.2011
Language:EN
[2011/14]
Type: A3 Search report 
No.:EP2305282
Date:18.05.2011
[2011/20]
Type: B1 Patent specification 
No.:EP2305282
Date:10.07.2013
Language:EN
[2013/28]
Search report(s)(Supplementary) European search report - dispatched on:EP14.04.2011
ClassificationIPC:A61K38/00, A61K38/28, A61K9/26, A61K33/06
[2011/14]
CPC:
C07K16/18 (EP,US); A61K31/00 (EP,US); A61K31/739 (EP,US);
A61K38/1709 (EP,US); A61K38/193 (EP,US); A61K39/0007 (EP,US);
A61K47/646 (EP,US); A61K9/2031 (EP,US); A61K9/2054 (EP,US);
A61K9/4866 (EP,US); A61P25/00 (EP); A61P25/28 (EP);
A61P37/00 (EP); A61P43/00 (EP); C07K14/4711 (EP,US);
A61K2039/505 (EP,US); A61K2039/53 (EP,US); A61K2039/55505 (EP,US);
A61K2039/55555 (EP,US); A61K2039/55566 (EP,US); A61K2039/55572 (EP,US);
A61K2039/55577 (EP,US); A61K2039/6037 (EP,US); A61K2039/605 (EP,US);
A61K39/00 (EP,KR,US); A61K9/0019 (EP,US); A61K9/2009 (EP,US);
A61K9/7023 (EP,US); C07K2317/24 (EP,US); C07K2317/567 (EP,US);
C07K2319/00 (EP,US) (-)
C-Set:
A61K38/193, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2011/14]
Extension statesAL17.11.2011
LT17.11.2011
LV17.11.2011
MK01.12.2011
RO17.11.2011
SI17.11.2011
TitleGerman:Vorbeugung und Behandlung von amyloidogener Krankheit[2011/14]
English:Prevention and treatment of amyloidogenic disease[2011/14]
French:Prévention et traitement de maladie amyloidogène[2011/14]
Examination procedure17.11.2011Examination requested  [2011/52]
28.12.2011Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
07.03.2012Amendment by applicant (claims and/or description)
21.05.2012Despatch of a communication from the examining division (Time limit: M02)
29.05.2012Observations by third parties
31.07.2012Reply to a communication from the examining division
17.01.2013Communication of intention to grant the patent
22.05.2013Fee for grant paid
22.05.2013Fee for publishing/printing paid
Parent application(s)   TooltipEP08011409.3  / EP1994937
EP98961833.5  / EP1033996
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP19980961833) is  02.08.2005
Opposition(s)Opponent(s)01  09.04.2014  13.05.2014  ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen Howard
Eli Lilly and Company Limited
8 Arlington Square West Downshire Way
Bracknell, Berkshire RG12 1PU / GB
 02  09.04.2014  13.05.2014  ADMISSIBLE
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
 03  10.04.2014  13.05.2014  ADMISSIBLE
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Tuxworth, Pamela M.
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014  13.05.2014  ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  10.04.2014  28.09.2015  WITHDRAWN
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
 06  10.04.2014  14.05.2014  ADMISSIBLE
Biogen Inc.
225 Binney Street
Cambridge MA 02142 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann
Patent- und Rechtsanwälte PartmbB
Postfach 860 820
81635 München / DE
 [N/P]
Former [2016/24]
Opponent(s)01  09.04.2014  13.05.2014  ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014  13.05.2014  ADMISSIBLE
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
 03  10.04.2014  13.05.2014  ADMISSIBLE
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Tuxworth, Pamela M.
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014  13.05.2014  ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  10.04.2014  28.09.2015  WITHDRAWN
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
 06  10.04.2014  14.05.2014  ADMISSIBLE
Biogen Inc.
225 Binney Street
Cambridge MA 02142 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann
Patentanwälte PartmbB
Postfach 860 820
81635 München / DE
Former [2015/45]
Opponent(s)01  09.04.2014  13.05.2014  ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014  13.05.2014  ADMISSIBLE
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
 03  10.04.2014  13.05.2014  ADMISSIBLE
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Tuxworth, Pamela M.
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014  13.05.2014  ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  10.04.2014  28.09.2015  WITHDRAWN
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
 06  10.04.2014  14.05.2014  ADMISSIBLE
Biogen Inc.
250 Binney Street
Cambridge, MA 02142 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Former [2015/43]
Opponent(s)01  09.04.2014  13.05.2014  ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014  13.05.2014  ADMISSIBLE
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
 03  10.04.2014  13.05.2014  ADMISSIBLE
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Tuxworth, Pamela M.
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014  13.05.2014  ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  10.04.2014  14.05.2014  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
 06  10.04.2014  14.05.2014  ADMISSIBLE
Biogen Inc.
250 Binney Street
Cambridge, MA 02142 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Former [2015/38]
Opponent(s)01  09.04.2014  13.05.2014  ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014  13.05.2014  ADMISSIBLE
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
 03  10.04.2014  13.05.2014  ADMISSIBLE
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Tuxworth, Pamela M.
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014  13.05.2014  ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  10.04.2014  14.05.2014  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
 06  10.04.2014  14.05.2014  ADMISSIBLE
Biogen Idec Inc.
133 Boston Post Road
Weston, MA 02493 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Former [2015/35]
Opponent(s)01  09.04.2014  13.05.2014  ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014  13.05.2014  ADMISSIBLE
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
 03  10.04.2014  13.05.2014  ADMISSIBLE
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014  13.05.2014  ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München / DE
 05  10.04.2014  14.05.2014  ADMISSIBLE
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG
Patent Department
4002 Basel / CH
 06  10.04.2014  14.05.2014  ADMISSIBLE
Biogen Idec Inc.
133 Boston Post Road
Weston, MA 02493 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Former [2014/21]
Opponent(s)01  09.04.2014    ADMISSIBLE
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014    ADMISSIBLE
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner
Siebertstrasse 4
81675 München / DE
 03  10.04.2014   
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
 04  09.04.2014    ADMISSIBLE
H. Lundbeck A/S
Ottilavej 9
2500Valby / DK
Opponent's representative
HOFFMANN EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München / DE
 05  10.04.2014    WITHDRAWN
Novartis AG
Lichtstrasse 35
4065 Basel / CH
Opponent's representative
Spinner, David Richard
Novartis Pharma AG Patent Department
4002 Basel / CH
 06  10.04.2014   
Biogen Idec MA Inc.
133 Boston Post Road
Weston, MA 02493 / US
Opponent's representative
Weiss, Wolfgang
Weickmann & Weickmann Patentanwälte Postfach 86 08 20
81635 München / DE
Former [2014/20]
Opponent(s)01  09.04.2014   
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285 / US
Opponent's representative
Ingham, Stephen H.
Eli Lilly and Company Ltd
European Patent Operations
Lilly Research Centre
Erl Wood Manor, Sunninghill Road
Windlesham, Surrey, GU20 6PH / GB
 02  09.04.2014   
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Opponent's representative
Vossius & Partner
Siebertstrasse 4
81675 München / DE
 03  10.04.2014   
Leeming, John Gerard
J.A. Kemp & Co.
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Opponent's representative
Woods, Geoffrey Corlett
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
23.05.2014Invitation to proprietor to file observations on the notice of opposition
03.02.2015Reply of patent proprietor to notice(s) of opposition
01.10.2015Cancellation of oral proceeding that was planned for 28.04.2016
28.04.2016Date of oral proceedings
08.06.2016Cancellation of oral proceeding that was planned for 22.06.2016
22.06.2016Date of oral proceedings
04.07.2016Despatch of communication that the patent will be revoked
09.11.2016Legal effect of revocation of patent [2016/51]
Appeal following opposition14.09.2016Appeal received No.  T2144/16
09.11.2016Result of appeal procedure: appeal of the proprietor withdrawn
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
07.03.2012Request for further processing filed
07.03.2012Full payment received (date of receipt of payment)
Request granted
22.03.2012Decision despatched
Fees paidRenewal fee
27.01.2011Renewal fee patent year 03
27.01.2011Renewal fee patent year 04
27.01.2011Renewal fee patent year 05
27.01.2011Renewal fee patent year 06
27.01.2011Renewal fee patent year 07
27.01.2011Renewal fee patent year 08
27.01.2011Renewal fee patent year 09
27.01.2011Renewal fee patent year 10
27.01.2011Renewal fee patent year 11
27.01.2011Renewal fee patent year 12
27.01.2011Renewal fee patent year 13
14.11.2011Renewal fee patent year 14
13.11.2012Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCH10.07.2013
CY10.07.2013
LI10.07.2013
MC10.07.2013
[2017/07]
Former [2014/33]CY10.07.2013
MC10.07.2013
Former [2014/10]CY10.07.2013
Documents cited:Search[XY]WO9116819  (MOLECULAR RX INC [US]);
 [Y]WO9400153  (SMITHKLINE BEECHAM BIOLOG [BE], et al);
 [X]EP0683234  (TAKEDA CHEMICAL INDUSTRIES LTD [JP]);
by applicantUS4666829
 GB2220211
 WO9007861
 WO9014837
 WO9110741
 US5057540
 WO9117271
 WO9118980
 WO9201047
 WO9213069
 EP0526511
 WO9306121
 US5208036
 WO9312227
 US5264618
 US5279833
 US5283185
 WO9408051
 US5314813
 WO9412629
 WO9505853
 US5399346
 WO9512608
 WO9530642
 WO9535503
 US5612486
 WO9717613
 WO9717614
otherEP1033996
 EP1690547
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.